Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae. The $7.22-per-share deal for 89.8% of Sage is a 30 ...

5:53 AM ESTHealth Care Sage rejects Biogen’s buyout offer, but says it's open to deals Sage rejects Biogen’s buyout offer, but says it's open to deals ...

Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal. Specific details of the lawsuit are not yet available ...

With Viatris taking home the biggest prize at this year’s Cannes Pharma Lions award and Biogen winning Gold, pharma is making a comeback. After a lackluster showing in 2024 extended a yearslong ...

Entering text into the input field will update the search result below Home page Seeking Alpha - Power to Investors Create free account ...

This data feed is not available at this time. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.